Corrigendum: Cemiplimab for advanced cutaneous squamous cell carcinoma in kidney transplant recipients (Néphrologie & Thérapeutique, (2022), 18, 5, (372), 10.1016/j.nephro.2022.07.395)

T. Van Meerhaeghe, J. F. Baurain, O. Bechter, C. Orte Cano, V. Del Marmol, A. Devresse, P. Doubel, M. Hanssens, R. Hellemans, D. Lienard, A. Rutten, B. Sprangers, A. Le Moine, S. Aspeslagh

Onderzoeksoutput: Comment/debate

Samenvatting

In the published article, there was a mistake in the Funding statement. The following statement should be removed: “TM declares that this study received funding from Sanofi and Bristol Myers Squibb. The funders were not involved in the study design, collection, analysis, interpretation of data, the writing of this article or the decision to submit it for publication”. The correct statement appears below.

Originele taal-2English
Artikelnummer1129134
Aantal pagina's2
TijdschriftFrontiers in nephrology
Volume2
DOI's
StatusPublished - 2022

Bibliografische nota

Publisher Copyright:
Copyright © 2023 Van Meerhaeghe, Baurain, Bechter, Orte Cano, Del Marmol, Devresse, Doubel, Hanssens, Hellemans, Lienard, Rutten, Sprangers, Le Moine and Aspeslagh.

Citeer dit